Picture the patient you saw last Tuesday. Sixty years old, diabetic foot ulcer that’s been open for six months, peripheral arterial disease, stage 3 chronic kidney disease, and a recent hospitalization for decompensated heart failure. You’ve already seen the notes from the SNF, the home health agency, and the ED visit two weeks ago. You’re the fifth clinician to touch this wound. And you’re working with a quality measure designed for a post-surgical patient with one problem.
This is the daily clinical reality of wound care. And embedded in that reality is a question that the healthcare system has never answered cleanly: what does this actually cost?
The honest answer is that nobody knows precisely. Not because the costs aren’t real — they are, and they are substantial — but because the data infrastructure to measure them accurately has never fully existed. Wound care spans multiple settings, gets coded under the wrong diagnoses, and serves a patient population so medically complex that isolating wound-attributable costs from the broader burden of diabetes, cardiovascular disease, and renal failure requires a level of analytical sophistication that most administrative datasets simply can’t support.
The result is a systematic underestimation of one of the most expensive conditions in American healthcare. The cost of chronic wounds is not a single number you can pull from a claims database. It’s layered across outpatient visits, hospitalizations, surgical interventions, post-acute care placements, amputations, and the long downstream tail of disability and mortality. And the further you get from the wound center, the harder those costs are to attribute back to the wound.
This article is about that measurement problem, why it matters clinically and financially, and why real-world outcomes data from wound care registries is the most credible path toward understanding and ultimately reducing what chronic wounds cost the healthcare system.
The Measurement Problem: Why Wound Care Costs Are Systematically Invisible
Ask a health economist to pull the cost of chronic wounds from Medicare claims data, and you’ll quickly run into a structural problem that clinicians in this specialty understand intuitively: wounds are often not coded as wounds.
A diabetic foot ulcer is frequently coded under the patient’s diabetes diagnosis. A pressure injury may disappear into a hospitalization claim coded primarily for sepsis. A venous leg ulcer shows up in the data as a dermatological encounter. This isn’t a documentation failure in the traditional sense — it’s a reflection of how ICD-10 coding prioritizes underlying etiology, and how wound care is often a secondary or tertiary concern in a complex encounter. As Dr. Caroline Fife and others in the wound care research community have documented, this coding pattern causes administrative datasets to systematically undercount both wound prevalence and the costs associated with wound care episodes.
The fragmentation problem compounds this. A single wound care episode may generate claims across an outpatient wound center, a vascular surgery practice, a home health agency, a skilled nursing facility, and an inpatient hospitalization — none of which are linked by a common wound identifier in claims data. The total episode cost is effectively invisible unless you have a mechanism to aggregate those encounters around the patient and the wound. Most health systems and payers do not have that mechanism.
Then there is the comorbidity entanglement. The patients who drive the highest wound care costs are also the patients with the most complex medical histories. When a patient with a diabetic foot ulcer, peripheral arterial disease, and renal failure is hospitalized for osteomyelitis, how much of that hospitalization cost is attributable to the wound, and how much to the underlying disease burden? Answering that question requires risk-adjusted analysis, not raw claims aggregation. Without risk adjustment, any cost estimate is either an overcount or an undercount depending on how the attribution is handled.
This is not an academic problem. When wound care costs are underestimated, the specialty is systematically undervalued. Payers underinvest in prevention. CMS designs quality measures that don’t reflect the actual patient population. Coverage decisions get made without adequate evidence. And wound care clinicians are left defending the value of their work with data that was never designed to capture it.
The measurement problem is, in a real sense, a policy problem. And it starts with the absence of a unified, wound-specific data infrastructure that can follow the patient across settings, risk-adjust for complexity, and produce outcomes data that actually reflects what wound care does and costs.
Where the Money Actually Goes: Direct Costs, Hospitalizations, and the Long Tail
When people think about wound care costs, they often think about the outpatient encounter: the wound center visit, the advanced dressing, the cellular tissue product. These are visible costs, and they are not trivial. Cellular tissue products (CTPs), negative pressure wound therapy (NPWT), hyperbaric oxygen therapy, and surgical debridement each represent meaningful per-episode expenditures across millions of patients annually.
But here is the framing that matters for understanding the true economic burden: outpatient wound care is a relatively small fraction of total wound-related cost. The real money is downstream.
Hospitalization is where the cost curve bends sharply upward. Infected wounds, osteomyelitis, and sepsis secondary to chronic wounds drive inpatient admissions that dwarf what was spent in the outpatient setting. A patient who cycles through six months of outpatient wound care without resolution and then presents to the ED with septic osteomyelitis generates an inpatient cost that can exceed the entire prior outpatient episode many times over. Readmissions compound this further: wound-related complications are a well-recognized driver of 30-day readmission rates, which carry both direct cost and financial penalty implications for hospital systems.
Post-acute care represents another substantial cost layer that rarely appears in wound care cost analyses. Patients discharged from inpatient stays to skilled nursing facilities for wound management, or enrolled in home health for wound care visits, generate ongoing costs that are attributed to post-acute care budgets rather than wound care budgets — even when the wound is the primary clinical driver. This accounting separation makes the wound care cost burden appear smaller than it is.
And then there are the indirect and downstream costs that are almost never captured: long-term disability, lost productivity for working-age patients with chronic wounds, caregiver burden, and the cost of long-term care placement for patients who lose functional independence after amputation or prolonged wound-related illness. These costs are real and substantial, but they exist outside the claims data that most wound care cost analyses rely on.
The practical implication is that the economic leverage in wound care is not primarily about reducing the cost of an outpatient visit or negotiating a better dressing price. It’s about preventing the hospitalization, the readmission, the amputation, and the post-acute placement. That’s where the financial case for investing in wound care quality — and in the data infrastructure to measure it — becomes compelling.
Amputation: The Economic Outcome That Changes Everything
Lower extremity amputation occupies a unique position in wound care economics. It is simultaneously one of the most feared clinical outcomes and one of the most expensive in all of medicine. And it is the outcome that most clearly illustrates why preventing wound complications is not just a clinical imperative but a financial one.
The costs of amputation extend far beyond the surgical episode. Rehabilitation, prosthetics, contralateral limb risk management, and the dramatically elevated mortality that follows major lower extremity amputation all represent ongoing financial and human costs that persist for years after the index procedure. Patients who undergo major amputation face substantially higher rates of subsequent hospitalization, functional decline, and mortality — costs that fall on payers, health systems, and patients themselves over a long time horizon.
This is where wound care real-world evidence becomes uniquely powerful. Clinical trials in wound care have a well-documented limitation: they typically enroll patients who are far less medically complex than the patients treated in actual wound centers. Patients with significant renal impairment, poorly controlled diabetes, or severe peripheral arterial disease — the patients who are at highest risk for amputation — are frequently excluded from the trials that generate the evidence base for coverage decisions.
Registry data fills that gap. When a wound care registry captures healing rates, time-to-heal, and amputation outcomes across a real-world population that includes the highest-acuity patients, it generates evidence that trial data simply cannot provide. That evidence answers the question payers and CMS actually need answered: does this intervention reduce amputation rates in the patients we’re actually paying to treat?
USWR has demonstrated this principle in practice. Registry data contributed to the evidence submitted in response to proposed CMS coverage changes affecting hyperbaric oxygen therapy — providing real-world outcomes data from the complex patient populations that trials had excluded. The mechanism matters here: it wasn’t advocacy alone, it was data. Specifically, risk-adjusted outcomes data from a population that reflected the actual clinical reality of the specialty.
For payers, the financial incentive to support amputation prevention is direct and quantifiable. For CMS, the alignment between quality outcomes and reduced downstream cost is exactly what value-based care frameworks are designed to reward. But none of that alignment can be demonstrated without the data infrastructure to show it.
Registry Data as a Cost-Reduction Mechanism
There’s a practical question that administrators and quality leaders often ask when evaluating registry participation: does better data actually change what wound care costs the system, or does it just measure the problem more accurately?
The answer, based on how quality improvement works in practice, is that measurement and improvement are inseparable. When clinicians track healing rates, offloading compliance, debridement frequency, and time-to-heal through a QCDR, they create accountability loops that drive care process improvements. And improved care processes reduce the downstream costs of complications, readmissions, and amputations.
This is not a theoretical argument. It reflects the basic mechanism of quality improvement in every specialty that has invested in registry-based reporting: you cannot improve what you cannot measure, and you cannot measure what you don’t systematically capture.
The risk-adjustment piece is critical here and often underappreciated. A wound center treating the highest-acuity patients — the ones with multiple comorbidities, renal failure, and advanced vascular disease — will appear to underperform on raw outcome metrics compared to a center treating simpler wounds. Without risk adjustment, quality reporting punishes clinicians for taking on complex patients, which is exactly the wrong incentive structure for a specialty that exists to manage wounds that other settings cannot handle.
Wound-specific QCDR measures, designed with the actual wound care patient population in mind, account for this complexity. They allow a wound center to demonstrate quality performance that reflects clinical reality rather than statistical artifact. That’s not just a MIPS compliance issue — it’s the foundation of a credible quality story that can withstand scrutiny from payers, accreditation bodies, and hospital administrators.
The economic argument for investing in wound care registry participation is, in this sense, inseparable from the cost-of-wounds argument. The same data infrastructure that helps individual practices avoid MIPS penalties and demonstrate quality performance is the infrastructure that generates the chronic wound outcomes data the specialty needs to defend its value to payers and CMS. These are not separate use cases — they are the same investment serving multiple purposes simultaneously.
MIPS, Wound Care, and the Real Financial Stakes of Underreporting
For wound care clinicians participating in MIPS, the cost of chronic wounds has a very direct and personal financial dimension: the MIPS payment adjustment that shows up in their Medicare reimbursement.
The structural disadvantage wound care clinicians face in MIPS is well-documented. The quality measures available through the traditional MIPS program were designed primarily for primary care and surgical specialties. They do not reflect the clinical realities of managing chronic, complex, comorbid patients in outpatient wound centers, podiatry practices, SNFs, or home health settings. Reporting on measures that weren’t designed for your patient population produces scores that don’t reflect actual quality — and may not produce competitive scores at all.
QCDR participation through a wound care-specific registry like USWR provides the alternative: validated, specialty-specific measures that reflect what wound care clinicians actually do and the patients they actually treat. This is the most defensible path to a competitive MIPS score for wound care providers, and it is the mechanism through which the specialty can participate meaningfully in value-based quality reporting rather than simply checking a compliance box.
The financial stakes are real and compounding. Negative MIPS payment adjustments accumulate year over year for clinicians who fail to report or report inadequately. The difference between a negative adjustment and no adjustment represents a meaningful financial gap, particularly for high-volume Medicare practices. For wound care clinicians who treat a predominantly Medicare population — which describes most outpatient wound centers — MIPS performance is not a peripheral compliance concern. It is a direct line item in practice economics.
For administrators and program directors, this creates a parallel set of concerns. Roster-wide MIPS performance data that reflects actual wound care complexity is the credibility currency needed to justify program investments, negotiate value-based contracts with payers, and demonstrate quality performance to hospital leadership. Generic measures that don’t capture wound care outcomes don’t serve that purpose, regardless of how well the practice performs on them.
The connection back to wound care costs is direct: the practices and programs that invest in wound-specific quality reporting are the ones that generate the data to demonstrate value, justify reimbursement for advanced interventions, and build the evidence base that protects the specialty from coverage cuts. MIPS compliance and wound care economics are not separate problems — they are expressions of the same underlying challenge.
Turning Cost Awareness Into Clinical and Policy Action
The cost of chronic wounds is not an abstract policy problem. It is the daily financial and clinical reality of every wound center managing non-healing wounds in high-acuity patients, every podiatry practice navigating diabetic foot ulcer care, and every home health agency trying to prevent the hospitalization that everyone knows is coming if the wound doesn’t turn.
Understanding the true cost of chronic wounds — the fragmented claims, the undercoded diagnoses, the hospitalization burden, the amputation economics, the MIPS stakes — clarifies what the specialty actually needs: a unified data infrastructure that can follow patients across settings, risk-adjust for complexity, and produce outcomes data credible enough to inform coverage decisions, justify advanced interventions, and demonstrate quality performance under scrutiny.
Wound care registries are that infrastructure. Not in a theoretical sense, but in a practical one. When clinicians submit quality data through a QCDR, they are simultaneously earning MIPS credit, contributing to the chronic wound outcomes data the specialty needs to defend itself, and generating the real-world evidence that researchers, payers, and industry cannot get from clinical trials alone.
The ask is not complicated, even if the problem is. Participate. Submit data. Use wound-specific measures that reflect your patient population. Let the data do the work that advocacy alone cannot.
USWR exists at the intersection of these needs: quality reporting for clinicians, outcomes data for the specialty, and real-world evidence for the policy and coverage conversations that determine whether wound care gets the resources it needs to do its job. Learn more about our services and how registry participation translates directly into better data, better scores, and a stronger evidence base for the specialty.
Recent Comments